157 related articles for article (PubMed ID: 7509620)
1. High-dose sequential chemo-radiotherapy with peripheral blood progenitor cell support for relapsed or refractory Hodgkin's disease--a 6-year update.
Gianni AM; Siena S; Bregni M; Lombardi F; Gandola L; Di Nicola M; Magni M; Peccatori F; Valagussa P; Bonadonna G
Ann Oncol; 1993 Dec; 4(10):889-91. PubMed ID: 7509620
[TBL] [Abstract][Full Text] [Related]
2. High-dose chemotherapy with autologous bone marrow transplantation in 50 advanced resistant Hodgkin's disease patients: an Italian study group report.
Carella AM; Congiu AM; Gaozza E; Mazza P; Ricci P; Visani G; Meloni G; Cimino G; Mangoni L; Coser P
J Clin Oncol; 1988 Sep; 6(9):1411-6. PubMed ID: 2458439
[TBL] [Abstract][Full Text] [Related]
3. [High-dose chemotherapy and autologous stem cell transplantation for refractory and relapsing Hodgkin's disease as first-line therapy-- studies at Sheba Medical Center--Tel Hashomer].
Avigdor A; Hardan I; Shpilberg O; Raanani P; Grotto I; Ben-Bassat I
Harefuah; 2000 Sep; 139(5-6):174-9, 248, 247. PubMed ID: 11062945
[TBL] [Abstract][Full Text] [Related]
4. Hybrid MOPP/ABVD and radiotherapy in advanced Hodgkin's disease.
Salvagno L; Sorarù M; Sotti G; Aversa S; Chiarion Sileni V; Mazzarotto R; Scarzello G; Bianco A; Pappagallo GL; Fiorentino MV
Ann Oncol; 1995 Feb; 6(2):173-9. PubMed ID: 7540419
[TBL] [Abstract][Full Text] [Related]
5. High-dose cyclophosphamide, carmustine (BCNU), and etoposide (VP16-213) with or without cisplatin (CBV +/- P) and autologous transplantation for patients with Hodgkin's disease who fail to enter a complete remission after combination chemotherapy.
Reece DE; Barnett MJ; Shepherd JD; Hogge DE; Klasa RJ; Nantel SH; Sutherland HJ; Klingemann HG; Fairey RN; Voss NJ
Blood; 1995 Jul; 86(2):451-6. PubMed ID: 7541661
[TBL] [Abstract][Full Text] [Related]
6. Combined chemotherapy-radiotherapy in advanced Hodgkin's disease: results of a prospective clinical trial with 70 stage IIIB-IV patients.
Fermé C; Lepage E; Brice P; D'Agay MF; Fermand JP; Castaigne S; Frija J; Miot C; Marty M; Gisselbrecht C
Int J Radiat Oncol Biol Phys; 1993 Jun; 26(3):397-405. PubMed ID: 7685749
[TBL] [Abstract][Full Text] [Related]
7. MOPP/ABV hybrid chemotherapy for advanced Hodgkin's disease significantly improves failure-free and overall survival: the 8-year results of the intergroup trial.
Glick JH; Young ML; Harrington D; Schilsky RL; Beck T; Neiman R; Fisher RI; Peterson BA; Oken MM
J Clin Oncol; 1998 Jan; 16(1):19-26. PubMed ID: 9440718
[TBL] [Abstract][Full Text] [Related]
8. Results of CAV regimen (CCNU, melphalan, and VP-16) as third-line salvage therapy for Hodgkin's disease.
Brusamolino E; Orlandi E; Canevari A; Morra E; Castelli G; Alessandrino EP; Pagnucco G; Bernasconi P; Astori C; Lazzarino M
Ann Oncol; 1994 May; 5(5):427-32. PubMed ID: 7521204
[TBL] [Abstract][Full Text] [Related]
9. MOPPEBVCAD chemotherapy with limited and conditioned radiotherapy in advanced Hodgkin's lymphoma: 10-year results, late toxicity, and second tumors.
Gobbi PG; Broglia C; Levis A; La Sala A; Valentino F; Chisesi T; Sacchi S; Corbella F; Cavanna L; Iannitto E; Pavone V; Molica S; Corazza GR; Federico M
Clin Cancer Res; 2006 Jan; 12(2):529-35. PubMed ID: 16428496
[TBL] [Abstract][Full Text] [Related]
10. Can MOPP be replaced in the treatment of advanced Hodgkin's disease?
Canellos GP
Semin Oncol; 1990 Feb; 17(1 Suppl 2):2-6. PubMed ID: 1689509
[TBL] [Abstract][Full Text] [Related]
11. Treatment of advanced Hodgkin's disease with chemotherapy--comparison of MOPP/ABV hybrid regimen with alternating courses of MOPP and ABVD: a report from the National Cancer Institute of Canada clinical trials group.
Connors JM; Klimo P; Adams G; Burns BF; Cooper I; Meyer RM; O'Reilly SE; Pater J; Quirt I; Sadura A; Shustik C; Skillings J; Sutcliffe S; Verma S; Yoshida S; Zee B
J Clin Oncol; 1997 Apr; 15(4):1638-45. PubMed ID: 9193364
[TBL] [Abstract][Full Text] [Related]
12. Randomized study of intensive MOPP-ABVD with or without low-dose total-nodal radiation therapy in the treatment of stages IIB, IIIA2, IIIB, and IV Hodgkin's disease in pediatric patients: a Pediatric Oncology Group study.
Weiner MA; Leventhal B; Brecher ML; Marcus RB; Cantor A; Gieser PW; Ternberg JL; Behm FG; Wharam MD; Chauvenet AR
J Clin Oncol; 1997 Aug; 15(8):2769-79. PubMed ID: 9256118
[TBL] [Abstract][Full Text] [Related]
13. Alternating MOPP and ABVD chemotherapy plus mantle-field radiation therapy in patients with massive mediastinal Hodgkin's disease.
Longo DL; Glatstein E; Duffey PL; Young RC; Ihde DC; Bastian AW; Wilson WH; Wittes RE; Jaffe ES; Hubbard SM; DeVita VT
J Clin Oncol; 1997 Nov; 15(11):3338-46. PubMed ID: 9363863
[TBL] [Abstract][Full Text] [Related]
14. [The management of Hodgkin's disease with chemotherapy or combined modality treatment].
Tsushita K; Utsumi M; Shimoyama M
Gan To Kagaku Ryoho; 1998 Dec; 25(14):2202-9. PubMed ID: 9881076
[TBL] [Abstract][Full Text] [Related]
15. Is there an effective salvage therapy for advanced Hodgkin's disease?
Canellos GP
Ann Oncol; 1991 Jan; 2 Suppl 1():1-7. PubMed ID: 1710484
[TBL] [Abstract][Full Text] [Related]
16. Outcome of treatment of first relapse of Hodgkin's disease after primary chemotherapy: identification of risk factors from the British Columbia experience 1970 to 1988.
Lohri A; Barnett M; Fairey RN; O'Reilly SE; Phillips GL; Reece D; Voss N; Connors JM
Blood; 1991 May; 77(10):2292-8. PubMed ID: 1709382
[TBL] [Abstract][Full Text] [Related]
17. Outcome of patients with Hodgkin's disease failing after primary MOPP-ABVD.
Bonfante V; Santoro A; Viviani S; Devizzi L; Balzarotti M; Soncini F; Zanini M; Valagussa P; Bonadonna G
J Clin Oncol; 1997 Feb; 15(2):528-34. PubMed ID: 9053474
[TBL] [Abstract][Full Text] [Related]
18. Alternating versus hybrid MOPP-ABVD in Hodgkin's disease: the Milan experience.
Viviani S; Bonadonna G; Santoro A; Zanini M; Zucali R; Negretti E; Valagussa P
Ann Oncol; 1991 Feb; 2 Suppl 2():55-62. PubMed ID: 1710921
[TBL] [Abstract][Full Text] [Related]
19. Bulky mediastinal Hodgkin's disease: results of a combined modality approach (ABVD/MOPP alternating chemotherapy plus radiation therapy).
De Lena M; Ditonno P; Lorusso V; Timurian A; Pellecchia A; Brandi M; Berardi F; Marzullo F
Haematologica; 1993; 78(4):230-5. PubMed ID: 7507457
[TBL] [Abstract][Full Text] [Related]
20. Prolonged disease-free survival after high-dose sequential chemo-radiotherapy and haemopoietic autologous transplantation in poor prognosis Hodgkin's disease.
Gianni AM; Siena S; Bregni M; Lombardi F; Gandola L; Valagussa P; Bonadonna G
Ann Oncol; 1991 Oct; 2(9):645-53. PubMed ID: 1720655
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
